Clinical trial
FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis…
NCT00425178 · CardioVascular BioTherapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT00425178 |
|---|---|
| Title | FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers |
| Official title | A Phase 1, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Patients With Diabetic or Venous Stasis Ulcers |
| Lead sponsor | CardioVascular BioTherapeutics, Inc., Industry |
| Collaborators | Warren General Hospital |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Wounds, Diabetes, Venous Stasis Ulcers |
| Intervention type | Drug |
| Interventions | FGF-1 |
| Enrollment | 8 |
| Start date | Sep 2, 2005 |
| Primary completion | Sep 2, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Jan 22, 2007 |
| Last update posted | Nov 1, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: